To hear about similar clinical trials, please enter your email below
Trial Title:
Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
NCT ID:
NCT05535894
Condition:
Pancreatic Cancer
Conditions: Official terms:
Pancreatic Neoplasms
Study type:
Observational
Overall status:
Unknown status
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Procedure
Intervention name:
Ablation of Celiac Ganglion
Description:
Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion
Arm group label:
Unresectable Pancreatic Cancer
Summary:
This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and
improvement in quality-of-life parameters for patients with advanced inoperable
pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of
EUS-RFA for pain control and improvement in quality-of-life parameters for patients with
advanced pancreatic cancer; 2) to measure the reduction of analgesic medications'
requirements in patients affected by inoperable pancreatic cancer.
Criteria for eligibility:
Study pop:
Patients with advanced pancreatic cancer who are deemed as non-surgical candidates
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Diagnosis of pancreatic cancer based on clinical, radiological, or pathological
assessment;
- Referred for abdominal and/or back pain due to pancreatic cancer;
- No prior history of RFA;
- Cancer pain unresponsive to the WHO 3-step analgesic ladder;
- Willingness to consent to participate in the study.
Exclusion Criteria:
- Patients who are not willing to give informed consent or agree to participate in the
study
- Surgically resectable pancreatic cancer;
- Abdominal pain with etiology other than pancreatic malignancy;
- Evidence of concurrent infection;
- Patients with irreversible coagulopathy international normalized ratio >1.5 or
platelet count <50,000/mm3),
- Patients with a preliminary diagnosis of adenocarcinoma are not possible established
with intraprocedural at EUS-guided FNA.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Shailendra Singh
Address:
City:
Morgantown
Zip:
26508
Country:
United States
Status:
Recruiting
Contact:
Last name:
Shailendra Singh, MD
Phone:
304-293-4123
Email:
shailendra.singh@hsc.wvu.edu
Contact backup:
Last name:
Arunkumar Krishnan
Phone:
3042937495
Email:
arunkumar.krishnan@hsc.wvu.edu
Investigator:
Last name:
Shailendra Singh, MD
Email:
Principal Investigator
Start date:
August 10, 2022
Completion date:
May 2024
Lead sponsor:
Agency:
West Virginia University
Agency class:
Other
Source:
West Virginia University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05535894
